atezolizumab plus bevacizumab

You have access
Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma
AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, TAIKAN HAMAMOTO, RYOTARO TANAKA, KAZUKI KUROSAKA, HIDEO SUZUKI and KENTA MOTOMURA

Anticancer Research September 2026, 46 (9) 5217-5227; DOI: https://doi.org/10.21873/anticanres.18366
You have access
Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab–Bevacizumab
HISANORI MUTO, TEIJI KUZUYA, YOSHIHIKO TACHI, YOSUKE NAGANO, YUTARO KAJINO, MISAE MATSUSHITA, SEIYA HAGIHARA, SATOSHI YAMAMOTO, TAKASHI KOBAYASHI, YOSHIAKI KATANO, NAOKI OHMIYA, SENJU HASHIMOTO, MIZUKI ARIGA, SAYAKA MORISAKI, GAKUSHI KOMURA, TAKUJI NAKANO, HIROYUKI TANAKA, KAZUNORI NAKAOKA, EIZABURO OHNO, KOHEI FUNASAKA, MITSUO NAGASAKA, RYOJI MIYAHARA and YOSHIKI HIROOKA

Anticancer Research March 2026, 46 (3) 1609-1618; DOI: https://doi.org/10.21873/anticanres.18056
You have access
Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, TAIKAN HAMOMOTO, KAZUKI KUROSAKA, HIDEO SUZUKI and KENTA MOTOMURA

Anticancer Research October 2025, 45 (10) 4627-4636; DOI: https://doi.org/10.21873/anticanres.17808
You have access
Mid-term Combination Immunotherapy and its Effect on the Albumin–Bilirubin Score in Unresectable Hepatocellular Carcinoma
AKIFUMI KUWANO, MASAYOSHI YADA, KOSUKE TANAKA, JUNRO TAKAHIRA, HIDEO SUZUKI and KENTA MOTOMURA

Anticancer Research April 2025, 45 (4) 1713-1721; DOI: https://doi.org/10.21873/anticanres.17552
Open Access
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma
NORIKAZU TANABE, ISSEI SAEKI, KENJI YAMAOKA, TOMOKAZU KAWAOKA, TETSU TOMONARI, JOJI TANI, TAKESHI TERASHIMA, YUSUKE KAWAMURA, SHIRO OKA, TETSUJI TAKAYAMA, HIDEKI KOBARA, TARO YAMASHITA, NORIO AKUTA, TAKAHIRO YAMASAKI and TARO TAKAMI

Anticancer Research March 2025, 45 (3) 1117-1125; DOI: https://doi.org/10.21873/anticanres.17499
You have access
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
NOBUAKI ISHIHARA, SHOHEI KOMATSU, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, TOSHIHIKO YOSHIDA, KENTARO TAI, KEISUKE ARAI, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, TAKANORI MATSUURA, TOSHIFUMI TADA, YUZO KODAMA and TAKUMI FUKUMOTO

Anticancer Research January 2025, 45 (1) 251-260; DOI: https://doi.org/10.21873/anticanres.17412
You have access
Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
TAKAFUMI YAMAMOTO, TAKANORI ITO, KAZUYUKI MIZUNO, SHINYA YOKOYAMA, KENTA YAMAMOTO, NORIHIRO IMAI, YOJI ISHIZU, TAKASHI HONDA and HIROKI KAWASHIMA

Anticancer Research September 2024, 44 (9) 4101-4111; DOI: https://doi.org/10.21873/anticanres.17239
You have access
Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study
TORU ISHIKAWA, SHUN YAMAZAKI, RYO SATO, RYO JIMBO, YUJI KOBAYASHI, TOSHIFUMI SATO, AKITO IWANAGA, TOMOE SANO, JUNJI YOKOYAMA and TERASU HONMA

Anticancer Research January 2024, 44 (1) 361-368; DOI: https://doi.org/10.21873/anticanres.16819
You have access
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index
MARA PERSANO, MARGHERITA RIMINI, TOSHIFUMI TADA, GOKI SUDA, SHIGEO SHIMOSE, MASATOSHI KUDO, JAEKYUNG CHEON, FABIAN FINKELMEIER, HO YEONG LIM, JOSÉ PRESA, GIANLUCA MASI, CHANGHOON YOO, SARA LONARDI, TIZIANA PRESSIANI, FABIO PISCAGLIA, TAKASHI KUMADA, LORENZA RIMASSA, MARIO SCARTOZZI, STEFANO CASCINU, ANDREA CASADEI-GARDINI and HCC COLLABORATIVE GROUP

Anticancer Research April 2023, 43 (4) 1599-1610; DOI: https://doi.org/10.21873/anticanres.16310
You have access
Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
SHOHEI KOMATSU, YOSHIHIKO YANO, MASAHIRO KIDO, KAORI KURAMITSU, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, SHINICHI SO, ATSUSHI YAMAMOTO, TADAHIRO GOTO, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, YOSHIHIDE UEDA, YUZO KODAMA and TAKUMI FUKUMOTO

Anticancer Research November 2022, 42 (11) 5479-5486; DOI: https://doi.org/10.21873/anticanres.16053

Main menu

User menu

Search

atezolizumab plus bevacizumab

Pages